IPCIQ (IntelliPharmaCeutics International) Beta: 0.9538 (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPCIQ IntelliPharmaCeutics International Inc IPCIQ
16 GF Score
Price $0.15
View Full Analysis

What is IntelliPharmaCeutics International Beta?

IntelliPharmaCeutics International IPCIQ -100.00% 16 Beta is 0.9538 as of Aug. 30, 2026. GuruFocus rates IPCIQ with a GF Score™ of 16/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-30), IntelliPharmaCeutics International's Beta is 0.9538.


IntelliPharmaCeutics International  (OTCPK:IPCIQ) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


IntelliPharmaCeutics International Beta Related Terms


IntelliPharmaCeutics International Beta Historical Data

* Premium members only.

The historical data trend for IntelliPharmaCeutics International's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International Beta Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.38 2.01 1.82 1.22 1.34

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.49 1.34 0.50 0.63 0.86

IPCIQ vs CHRO, KTTA, FRTX: Beta Comparison

For the Biotechnology subindustry, IntelliPharmaCeutics International's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Beta distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Beta falls into.


IPCIQ
16GF Score
IntelliPharmaCeutics International Inc IPCIQ
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IntelliPharmaCeutics International Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.9538 mean?
IntelliPharmaCeutics International (IPCIQ) has a Beta of 0.9538 as of Aug. 30, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for IntelliPharmaCeutics International and its competitors.
Is IntelliPharmaCeutics International's Beta too high?
IntelliPharmaCeutics International's current Beta is 0.9538. Overall, IntelliPharmaCeutics International has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does IntelliPharmaCeutics International's Beta compare to CHRO and KTTA?
IntelliPharmaCeutics International's Beta of 0.9538 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for IntelliPharmaCeutics International and its competitors. IntelliPharmaCeutics International's current Beta is 0.9538. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IntelliPharmaCeutics International stock overvalued right now?
IntelliPharmaCeutics International (IPCIQ) has a current Beta of 0.9538. The current Beta is 0.9538. IntelliPharmaCeutics International's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For IntelliPharmaCeutics International (IPCIQ), the current Beta is 0.9538 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IntelliPharmaCeutics International Business Description

Address 30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline.
16GF Score

Get the complete analysis for IPCIQ

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price